Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: A retrospective cohort study of 738 patients

International Journal of Cancer

Volumn 87, Issue 5, 2000, Pages 741-749

  Tanaka, Hideo ^a,h   Tsukuma, Hideaki ^a   Kasahara, Akinori ^b   Hayashi, Norio ^c   Yoshihara, Harumasa ^d   Masuzawa, Manabu ^e   Kanda, Tsutomu ^f   Kashiwagi, Tohoru ^g   Inoue, Atsuo ^a   Kato, Michio ^e   Oshima, Akira ^a   Kinoshita, Yoko ^a   Kamada, Takenobu ^d  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b OSAKA UNIVERSITY HOSPITAL   (Japan)

^c OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^d OSAKA ROSAI HOSPITAL   (Japan)

^e OSAKA NATIONAL HOSPITAL   (Japan)

^f OSAKA GENERAL MEDICAL CENTER   (Japan)

^g OSAKA KOSEI NENKIN HOSPITAL   (Japan)

^h NONE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER STAGING; CHRONIC HEPATITIS; COHORT ANALYSIS; DRUG EFFECT; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL RATE; THROMBOCYTE COUNT; VIRUS INFECTION;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CAUSE OF DEATH; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INTERFERON ALFA-2A; INTERFERON ALFA-2B; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 0033861568     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20000901)87:5<741::AID-IJC18>3.0.CO;2-B     Document Type: Article

References (44)

1. BENVEGNU, L., CHEMELLO, L., NOVENTA, F., FATTOVICH, G., PONTISSO, P. and ALBERTI, A., Retrospective analysis of the effect of Interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer, 83, 901-909 (1998).
2. BRUNETTO, M.R., OLIVERI, F., KOEHLER, M., ZAHM, F., BONINO, F. and the International Interferon-α Hepatocellular Carcinoma Study Group, Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet, 351, 1535-1539 (1998).
3. CAMMA, C., GIUNTA, M., PINZELLO, G., MORABITO, A., VERDERIO, P. and PACLIARO, L., Chronic hepatitis C and Interferon alpha: conventional and cumulative meta-analyses of randomized controlled trials. Amer. J. Gastroenterol., 94, 581-595 (1999).
4. CAUSSE, X., GODINOT, H., CHEVALLIER, M., CHOSSEGROS, P., ZOULIM, F., OUZAN, D., HEYRAUD, J.P., FONTANUES, T., ALBRECHT, J. and MESCHIEVITZ, C., Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology, 101, 497-502 (1991).
5. DAVIS, G.L., BALART, LA., SCHIFF, E.R., LINDSAY, K., BODENHEIMER, H.C. JR., PERRILLO, R.P., CAREY, W., JACOBSON, I.M., PAYNE, J. and DIENSTAG, J.L., Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N. Engl. J. Med., 321, 1501-1506 (1989).
6. DI BISCEGLIE, A.M., MARTIN, P., KASSIANIDES, C., LISKER-MELMAN, M., MURRAY, L., WAGGONER, J., GOODMAN, Z., BANKS, S.M. and HOOFNAGLE, J.H., Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N. Engl. J. Med., 321, 1506-1510 (1989).
7. FATTOVICH, G., GIUSTINA, G., DEGOS, F., DIODATI, G., TREMOLADA, F., NEVENS, F., ALMASIO, P., SOLINAS, A., BROUWER, J.T., THOMAS, H., REALDI, G., CORROCHER, R. and SCHALM, S.W., Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EURO-HEP). J. Hepatol., 27, 201-205 (1997).
8. HAGIWARA, H., HAYASHI, N., KASAHARA, A., OSHITA, M., KATAYAMA, K., KATO, M., MASUZAWA, M., FUSAMOTO, H., SAKURAI, M. and KAMADA, T., Treatment with recombinant interferon-α 2a for patients with chronic hepatitis C: predictive factors for biochemical and virologic response. Scand. J. Gastroenterol., 31, 1021-1026 (1996).
9. HAGIWARA, H., HAYASHI, N., MITA, E., TAKEHARA, T., KASAHARA, A., FUSAMOTO, H. and KAMADA, T., Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology, 104, 877-883 (1993).
10. HANAI, A., AJIKI, W., TSUKUMA, H., OSHIMA, A. and FUJIMOTO, I., Osaka Cancer Registry. In D.M. Parkin, S.L. Whelan, J. Ferlay, L. Raymond, and J. Young (eds.), Cancer incidence in five continents, vol. VII, no. 32, pp. 394-401, IARC, Lyon (1997).
11. HINO, K., SAINOKAMI, S., SHIMODA, K., IINO, S., WANG, Y., OKAMOTO, H., MIYAKAWA, Y. and MAYUMI, M., Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. J. med. Virol., 42, 299-305 (1994).
12. HOOFNAGLE, J.H., MULLEN, K.D., JONES, D.B., RUSTGI, V., DI BISCEGLIE, A., PETERS, M., WAGGONER, J.G., PARK, Y. and JONES, E.A., Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. M Engl. J. Med., 315, 1575-1578 (1986).
13. IARC WORKING GROUP ON THE EVALUATION OF CARCINOGENIC RISKS TO HUMANS, IACR monographs on the evaluation of carcinogenic risks to humans. Hepatitis C virus, vol. 59, IARC, Lyon (1994).
14. IKEDA, K., SAITOH, S., ARASE, Y., CHAYAMA, K., SUZUKI, Y., KOBAYASHI, M., TSUBOTA, A., NAKAMURA, I., MURASHIMA, N., KUMADA, H. and KAWANISHI, M., Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology, 29, 1124-1130 (1999).
15. IKEDA, K., SAITOH, S., SUZUKI, Y., KOBAYASHI, M., TSUBOTA, A., KOIDA, I., ARASE, Y., FUKUDA, M., CHAYAMA, K., MURASHIMA, N. and KUMADA, H., Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J. Hepatol., 28, 930-938 (1998).
16. IMAI, Y., KAWATA, S., TAMURA, S., YABUUCHI, I., NODA, S., INADA, M., MAEDA, Y., SHIRAI, Y., FUKUZAKI, T., KAJI, I., ISHIKAWA, H., MATSUDA, Y., NISHIKAWA, M. and 2 OTHERS, Relation of interferon therapy and hepato-cellular carcinoma in patients with chronic hepatitis C. Ann. intern. Med., 129, 94-99 (1998).
17. KASAHARA, A., HAYASHI, N., MOCHIZUKI, K., TAKAYANAGI, M., YOSHIOKA, K., KAKUMU, S., IIJIMA, A., URUSHIHARA, A., KIYOSAWA, K., OKUDA, M., HINO, K. and OKITA, K., Risk factors for hepatocellular carcinoma and its incidence after inteferon treatment in patients with chronic hepatitis C. Hepatalogy, 27, 1394-1402 (1998).
18. KNODELL, R.G., ISHAK, K.G., BLACK, W.C., CHEN, T.S., CRAIG, R., KAPLOWITZ, N., KIERNAN, T.W. and WOLLMAN, J., Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology; 1, 431-435 (1981).
19. KUZUSHITA, N., HAYASHI, N., KATAYAMA, K., KANTO, T., OSHITA, M., HAGIWARA, H., KASAHARA, A., FUSAMOTO, H. and KAMADA, T., High levels of serum interleukin-10 are associated with a poor response to Interferon treatment in patients with chronic hepatitis C. Scand. J. Gastroenterol., 32, 169-174 (1997).
20. LAU, J.Y., DAVIS, G.L., KNIFFEN, J., QIAN, K.P., URDEA, M.S., CHAN, C.S., MIZOKAMI, M., NEUWALD, P.D. and WILBER, J.C., Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet, 341, 1501-1504 (1993).
21. MARCELLIN, P., BOYER, N., GIOSTRA, E., DEGOTT, C., COUROUCÉ, A.M., DEGOS, F., COPPERE, H., CALES, P., COUZIGOU, P. and BENHAMOU, J.P., Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology, 13, 393-397 (1991).
22. MARCELLIN, P., POUTEAU, M., MARTINOT-PEIGNOUX, M., DEGOS, F., DUCHATELLE, V., BOYER, N., LEMONNIER, C., DEGOTT, C., ERLINGER, S. and BENHAMOU, J.P., Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology, 109, 156-165. (1995).
23. MAZZELLA, G., ACCOGLI, E., SOTTILI, S., FESTI, D., ORSINI, M., SALZETHA, A., NOVELLI, V., CIPOLLA, A., FABBRI, C., PEZZOLI, A. and RODA, E., Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-relaled liver cirrhosis. J. Hepatol., 24, 141-147 (1996).
24. MORENO, M.G. and MURIEL, P., Remission of liver fibrosis by interferon-alpha 2b. Biochem. Pharmacol., 50, 515-520 (1995).
25. NIEDERAU, C., LANGE, S., HEINTGES, T., ERHARDT, A., BUSCHKAMP, M., HÜRTER, D., NAWROCKI, M., KRUSKA, L., HENSEL, F., PETRY, W. and HÄUSSINGER, D., Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology, 28, 1687-1695 (1998).
26. NISHIGUCHI, S., KUROKI, T., NAKATANI, S., MORIMOTO, H., TAKEDA, T., NAKAJIMA, S., SHIOMI, S., SEKI, S., KOBAYASHI, K. and OTANI, S., Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet, 346, 1051-1055 (1995).
27. OKAMOTO, H., SUGIYAMA, Y., OKADA, S., KURAI, K., AKAHANE, Y., SUGAI, Y., TANAKA, T., SATO, K., TSUDA, F. and MIYAKAWA, Y., Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J. gen. Virol., 73, 673-679 (1992).
28. OSHIMA, A., AJIKI, W., TANAKA, H. and TSUKUMA, H., Significance and usefulness of cancer registries. Int. J. clin. Oncol., 3, 343-350 (1998).
29. PARIANTE, C.M., GERMANA, ORRU, M., BAITA, A., FARCI, M.G. and CARPINIELLO, B., Treatment with interferon-α in patients with chronic hepatitis and mood or anxiety disorders. Lancet, 354, 131-132 (1999).
30. SERFATY, L., AUMAITRE, H., CHAZOUILLERES, O., BONNAND, A.M., ROSMORDUC, O., POUPON, R.E. and POUPON, R., Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepalology, 27, 1435-1440 (1998).
31. SHINDO, M., ARAI, K., SOKAWA, Y. and OKUNO, T., Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon-α therapy. Ann. intern. Med., 122, 586-591 (1995).
32. SHIRATORI, Y., KATO, N., YOKOSUKA, O., IMAZEKI, F., HASHIMOTO, E., HAYASHI, N., NAKAMURA, A., ASADA, M., KURODA, H., TANAKA, N., ARAKAWA, Y. and OMATA, M., Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Gastroenterology, 113, 558-566 (1997).
33. SIMMONDS, P., ALBERTI, A., ALTER, H.J., BONINO, F., BRADLEY, D.W., BRECHOT, C., BROUWER, J.T., CHAN, S.W., CHAYAMA, K. and CHEN, D.S., A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology, 19, 1321-1324 (1994).
34. TAKANO, S., YOKOSUKA, O., IMAZAKI, F., TAGAWA, M. and OMATA, M., Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology, 21, 650-655 (1995).
35. TANAKA, H., HIYAMA, T., TSUKUMA, H., FUJIMOTO, I., YAMANO, H., OKUBO, Y. and KITADA, A., Cumulative risk of hepatocellular carcinoma in hepatitis C virus carriers: statistical estimations from cross-sectional data. Jpn. J. Cancer Res., 85, 485-490 (1994a).
36. TANAKA, T., TSUKIYAMA-KOHARA, K., YAMAUUCHI, K., YAGI, S., TANAKA, S., HASEGAWA, A., OHTA, Y., HATTORI, N. and KOHARA, M., Significance of specific antibody assay for genotyping of hepatitis C viruses. Hepatology, 19, 1347-1353 (1994b).
37. TANAKA, H. and TSUKUMA, H., Hepatitis C virus. In J. Tooze (ed.), Cancer survey, vol. 33, Cold Spring Harbor Laboratory Press, New York (1999).
38. TANAKA, H., TSUKUMA, H., MASAOKA, T., AJIKI, W., KOYAMA, Y., KINOSHITA, N., HASUO, S. and OSHIMA, A., Suicide risk among cancer patients: experiences at one medical center in Japan, 1978-1994. Jpn. J. Cancer. Res., 90, 812-817 (1999).
39. TANAKA, H., TSUKUMA, H., YAMANO, H., OKUBO, Y., INOUE, A., KASAHARA, A. and HAYASHI, N., Hepatitis C virus 1b (II) infection and development of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma: a case-control study in Japan. J. Epidemiol., 8, 244-249 (1998).
40. TSUBOTA, A., CHAYAMA, K., IKEDA, K., ARASE, Y., KOIDA, I., SAITOH, S., HASHIMOTO, M., IWASAKI, S., KOBAYASHI, M. and HIROMITSU, K., Factors predictive of response to interferon-α therapy in hepatitis C virus infection. Hepatology, 19, 1088-1094 (1994).
41. TSUKUMA, H., HIYAMA, T., TANAKA, S., NAKAO, M., YABUUCHI, T., KITAMURA, T., NAKANISHI, K., FUJIMOTO, I., INOUE, A., YAMAZAKI, H. and KAWASHIMA, T., Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N. Engl. J. Med., 328, 1797-1801 (1993).
42. VALLA, D.C., CHEVALLIER, M., MARCELLIN, P., PAYEN, J.L., TREPO, C., FONCK, M., BOURLIERE, M., BOUCHER, E., MIGUET, J.P., PARLIER, D., LEMONNIER, C. and OPOLON, P., Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology, 29, 1870-1875 (1999).
43. YOSHIDA, H., SHIRATORI, Y., MORIYAMA, M., ARAKAWA, Y., IDE, T., SATA, M., INOUE, O., YANO, M., TANAKA, M., FUJIYAMA, S., NISHIGUCHI, S., KUROKI, T., IMAZEKI, F. and 4 OTHERS, Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann. Intern. Med., 131, 174-181 (1999).
44. YUKI, N., HAYASHI, N., KASAHARA, A., HAGIWARA, H., TAKEHARA, T., OSHITA, M., KATAYAMA, K., FUSAMOTO, H. and KAMADA, T., Pretreatment viral load and response to prolonged interferon-α course for chronic hepatitis C. J. Hepatol., 22, 457-463 (1995).